Skip to main content
OpenTrials
Completed

NCT Number: NCT07561801

Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pentoxifylline Chronic Disease Chronic Kidney Disease Contrast Induced Nephropathy Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Intensive Care Unit Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

Contrast-induced acute kidney injury (AKI), which is also known as contrast-induced nephropathy (CIN), is defined as the development of AKI following contrast medium exposure, without an alternative aetiology.

Recently, the cyclic nucleotide phosphodiesterase (PDE) has emerged as a promising target for pharmacological intervention against chronic kidney disease (CKD) progression.

The nonselective PDE inhibitor pentoxifylline (PTX) is a methyl xanthine derivative. It's an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. In addition to its classic indication for intermittent claudication. It has been used primarily to treat patients with peripheral arterial insufficiency.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 65 years.
  • Both sexes.
  • The presence of chronic kidney disease (CKD) is defined according to the National Kidney Foundation-kidney disease Outcomes Quality Initiative guidelines with second or third stage.
  • Urgent patients expected taking dye in stable cases of cardiac catheterization or pulmonary embolism with Geneva score (4-11).

Exclusion criteria

  • Patients with CKD on renal replacement therapy.
  • Respiratory failure.
  • Cardiac failure.
  • Liver failure.
  • Methylxanthines hypersensitivity.

Treatment and study plan

Pentoxifylline

Drug

Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day [dose adjustment according to estimated glomerular filtration rate (eGFR)] from 24 hr before contrast to 48 hr after contrast procedure.

normal saline

Drug

Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.

Primary outcomes

  1. Incidence of contrast induced nephropathy

    Time frame: 48 hours after contrast procedure.

    Incidence of contrast induced nephropathy was recorded.

Secondary outcomes

  1. Progress of glomerular filtration rate

    Time frame: 48 hours after contrast procedure.

    Progress of glomerular filtration rate after use of pentoxifylline was recorded.

  2. Lenght of intensive care unit stay

    Time frame: Till the end of procedure (Up to 4 hours)

    Lenght of intensive care unit stay was recorded.

  3. Need of dialysis

    Time frame: 48 hours after contrast procedure.

    Need of dialysis was recorded.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

The Role of Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.